Triptolide Upregulates Myocardial Forkhead Helix Transcription Factor p3 Expression and Attenuates Cardiac Hypertrophy by Yuan-Yuan Ding et al.
fphar-07-00471 November 28, 2016 Time: 12:6 # 1
ORIGINAL RESEARCH




King’s College London, UK
Reviewed by:
Juan Badimon,







†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 29 August 2016
Accepted: 18 November 2016
Published: 30 November 2016
Citation:
Ding Y-Y, Li J-M, Guo F-J, Liu Y,
Tong Y-F, Pan X-C, Lu X-L, Ye W,
Chen X-H and Zhang H-G (2016)
Triptolide Upregulates Myocardial
Forkhead Helix Transcription Factor





Forkhead Helix Transcription Factor
p3 Expression and Attenuates
Cardiac Hypertrophy
Yuan-Yuan Ding1†, Jing-Mei Li1†, Feng-Jie Guo2, Ya Liu3, Yang-Fei Tong1,4, Xi-Chun Pan1,
Xiao-Lan Lu1,5, Wen Ye1, Xiao-Hong Chen1 and Hai-Gang Zhang1*
1 Department of Pharmacology, College of Pharmacy, Third Military Medical University, Chongqing, China, 2 The People’s
Liberation Army No. 309 Hospital, Beijing, China, 3 Institute of Materia Medica and Department of Pharmaceutics, College of
Pharmacy, Third Military Medical University, Chongqing, China, 4 Department of Pharmacy, Chongqing Traditional Medicine
Hospital, Chongqing, China, 5 Department of Clinical Laboratory, First Affiliated Hospital of North Sichuan Medical College,
Nanchong, China
The forkhead/winged helix transcription factor (Fox) p3 can regulate the expression of
various genes, and it has been reported that the transfer of Foxp3-positive T cells could
ameliorate cardiac hypertrophy and fibrosis. Triptolide (TP) can elevate the expression
of Foxp3, but its effects on cardiac hypertrophy remain unclear. In the present study,
neonatal rat ventricular myocytes (NRVM) were isolated and stimulated with angiotensin
II (1 µmol/L) to induce hypertrophic response. The expression of Foxp3 in NRVM was
observed by using immunofluorescence assay. Fifty mice were randomly divided into
five groups and received vehicle (control), isoproterenol (Iso, 5 mg/kg, s.c.), one of
three doses of TP (10, 30, or 90 µg/kg, i.p.) for 14 days, respectively. The pathological
morphology changes were observed after Hematoxylin and eosin, lectin and Masson’s
trichrome staining. The levels of serum brain natriuretic peptide (BNP) and troponin
I were determined by enzyme-linked immunosorbent assay and chemiluminescence,
respectively. The mRNA and protein expressions of α- myosin heavy chain (MHC),
β-MHC and Foxp3 were determined using real-time PCR and immunohistochemistry,
respectively. It was shown that TP (1, 3, 10 µg/L) treatment significantly decreased
cell size, mRNA and protein expression of β-MHC, and upregulated Foxp3 expression
in NRVM. TP also decreased heart weight index, left ventricular weight index and,
improved myocardial injury and fibrosis; and decreased the cross-scetional area of the
myocardium, serum cardiac troponin and BNP. Additionally, TP markedly reduced the
mRNA and protein expression of myocardial β-MHC and elevated the mRNA and protein
expression of α-MHC and Foxp3 in a dose-dependent manner. In conclusion, TP can
effectively ameliorate myocardial damage and inhibit cardiac hypertrophy, which is at
least partly related to the elevation of Foxp3 expression in cardiomyocytes.
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INTRODUCTION
Cardiac hypertrophy is a pathological feature of various cardiac
diseases, including hypertension, cardiomyopathy, valvular
dysfunction, myocardial infarction, etc., and also the strongest
predictor for the development of heart failure, arrhythmia,
and sudden death (van Berlo et al., 2013; Frieler and
Mortensen, 2015). It has been identified as a significant
independent risk factor for cardiac diseases and suggested
to be the primary therapeutic goal for hypertension and
chronic heart failure (Chemaly et al., 2013; Verschuren et al.,
2014; Ikeda et al., 2015). In order to maintain cardiac
output, some compensatory mechanisms are activated, such
as the Frank-Starling response, neuroendocrine activation, and
inflammatory reaction (van Berlo et al., 2013; Kessler et al.,
2014). Inflammation and the activation of immune system are
involved in orchestrating this complex pathological response.
It has been shown that the functions of regulatory T (Treg)
cells are decreased in patients with chronic heart failure and
cardiac hypertrophy (McKinsey, 2012), which implies that Treg
cells are involved in the pathophysiological process of cardiac
hypertrophy.
The forkhead/winged helix transcription factor (Fox) p3 is
a key transcription factor that largely controls the phenotype
and function of Treg cells (Hori et al., 2003). And Treg cells
also need continuous high expression of Foxp3 to maintain
immune homeostasis (Sakaguchi et al., 2008; Klein et al., 2013).
Foxp3 can depress the activation of immune cells and their
migration to myocardium (Matsumoto et al., 2011), reduce
the cardiac interstitial inflammatory cell infiltration and the
secretion of cytokines, and then ameliorate cardiac hypertrophy
and myocardial damage induced by angiotensin II (AngII) or
high blood pressure. It has been reported that adoptive transfer of
Treg cells into AngII–infused hypertensive mice could improve
cardiac hypertrophy and ameliorate cardiac fibrosis despite
sustained hypertension (Kvakan et al., 2009; Kasal et al., 2012).
Although Foxp3 has been considered as a characteristic
marker of Treg cells, it is found to be expressed in a variety of
cells, such as other immune cells, hematopoietic cells, epithelial
cells and tumor cells from multiple sources (Katoh et al., 2010;
Ladoire et al., 2011; Kasal et al., 2012). Regarding its role as a
transcription regulator, its regulatory mechanism in the process
of cardiac hypertrophy is still unclear.
Triptolide (TP) is an epoxy-2-terpenoid ester compound
extracted from the Chinese traditional herb Leigongteng
(Tripterygium wilfordii Hook. f.), which has been used for the
treatment of rheumatoid arthritis, systemic lupus erythematosus,
discoid lupus erythematosus, psoriasis, asthma and cancers (Liu,
2011; Fan et al., 2016; Ziaei and Halaby, 2016). It has been
suggested that TP treatment could enhance the expression of
Foxp3 in CD4+ cells (Zhang et al., 2009; Zheng et al., 2013)
and attenuate the development of pulmonary arterial neointimal
formation (Faul et al., 2000) and the proliferation of fibroblasts
in the heart and airway (Leonard et al., 2002; Zhang et al.,
2013). However, the effects of TP on cardiac hypertrophy and its
mechanism are at present poorly understood. Therefore, the aims
of the present study were to explore the regulating effect of TP




Fifty healthy male Kunming mice weighing 20–28 g were
randomly divided into 5 groups (n = 10 in each group), i.e.,
normal control, myocardial hypertrophy model group and TP
(10, 30, 90 µg/kg) treated groups. Mice in the model group
(isoproterenol treated group, Iso) and TP groups were injected
subcutaneously with (±)isoproterenol hydrochloride (Sigma, St.
Louis, MO, USA) 5 mg/kg once daily for 14 days to induce
cardiac hypertrophy according to the method described by Ma
and other researchers (Ma et al., 2011; Song et al., 2013). Animals
in the TP groups were intraperitoneally injected with TP (purity
99.69%; Beijing Medicass Biotechnol, Beijing, China) at doses
of 10, 30, or 90 µg/kg daily, respectively, for 14 days. Those in
the control group were injected with an equal volume of normal
saline simultaneously. The mice in all groups were weighed every
3 days and the doses were adjusted accordingly. All animals were
housed under conditions of controlled temperature (20–25◦C)
and humidity (60–65%), and a 12-h light-dark cycle and were
fed with standard food and water ad libitum. This investigation
conformed to The Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996) and was approved
by the Ethical Committee for Animal Experimentation of the
Third Military Medical University. Humane end points were set
according to the OECD Guidance Document on the Recognition,
Assessment, and Use of Clinical Signs as Humane End points for
Experimental Animals Used in Safety Evaluation1 .
Sampling
At the end of treatments, all animals were weighted and
anesthetized with pentobarbital sodium (50 mg/kg, i.p.). Blood
was sampled from the abdominal aorta and allowed to coagulate
at 37◦C for 2 h. After centrifugation at 4000 rpm for 10 min,
the suspension were collected and stored at −20◦C. The mice
were decapitated and the hearts were excised and placed in
a dish with normal saline, then blotted on filter paper and
weighed to calculate the ratio of heart weight to body weight
(HW/BW) and the ratio of left ventricular weight to body weight
(LVW/BW). Tibial length (TL) was measured to calculate the
ratio of heart weight or left ventricular weight to tibial length
(HW/TL, LVW/TL). The mid-ventricle was fixed with a formalin
neutral buffer solution and embedded in paraffin. The apex of the
ventricle was stored in liquid nitrogen for future use.
Cell Culture
Neonatal rat ventricular myocytes (NRVM) from 1 to 2 days
old Sprague-Dawley rats were isolated and cultured as described
previously (Yang et al., 2013; Lu et al., 2015). After being cultured
in serum-free DMEM for 24 h, the cells were incubated for
1https://www.aaalac.org/accreditation/RefResources/RR_HumaneEndpoints.pdf
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FIGURE 1 | Triptolide attenuated the hypertrophic response of neonatal rat ventricular myocytes. Hypertrophic response of neonatal rat ventricular
myocytes (NRVM) was induced by angiotensin II (Ang II). (A) NRVM treated with Ang II (1 µmol/L) and triptolide (TP) for 24 h, stained with rhodamine-phalloidin
(bar = 50 µm); (B) cell size (n = 50 cells in each group); (C) β-MHC mRNA expression determined using Real-time PCR (n = 4); (D) β-MHC expression level
determined using Western blotting (n = 4). The data are presented as mean ± SEM, ∗∗p < 0.01 compared with the control group; #p < 0.05, ##p < 0.01 compared
with the Ang II-treated group (one-way ANOVA).
24 h in a non-serum medium containing 1 µmol/L AngII.
Different concentrations of TP (1, 3, or 10 µg/L) were added
simultaneously. The cell size was determined with rhodamine-
labeled phalloidin staining and analyzed with ImageJ software
(NIH Image, National Institutes of Health, Bethesda, MD, USA2).
Immunofluorescence Staining
Neonatal rat ventricular myocytes were isolated and cultured
as described above. Myocytes cultured on glass coverslips were
fixed with 4% (w/v) paraformaldehyde for 30 min at room
temperature. NRVMs were subjected to immunofluorescence
with a primary α-actinin polyclonal rabbit antibody and
primary Foxp3 mouse monoclonal antibody (1:100, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and a secondary anti-
rabbit antibody conjugated to Alexa Fluor 555 and secondary
anti-mouse antibody conjugated to fluor 488, respectively. Cells
were co-stained with DAPI to visualize their nuclei. A negative
control was carried out by replacing the primary antibody with
isotype IgG. The expression of Foxp3 in NRVMs was observed
by laser scanning confocal microscopy (LSM 780 AxioObserver,
2http://rsbweb.nih.gov/ij/
Carl Zeiss Microscopy, München, Germany) and analyzed by
ZEN imaging software (2012, blue edition, Carl Zeiss).
Western Blot Assay
The β-MHC expression of NRVM was determined with
Western blotting method. Total cellular homogenates were
prepared, and 30 µg of the denatured proteins were loaded
and separated using SDS-PAGE. The proteins were transferred
onto a PVDF membrane (Millipore, Bedford, MA, USA) and
incubated with a primary β-MHC antibody (1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at 4◦C overnight,
followed by horseradish peroxidase (HRP)-conjugated secondary
antibody. Chemiluminescence was detected with an ECL
detection kit (Millipore, Bedford, MA, USA).
Morphometric Analysis of Myocardial
Tissue
Left ventricle tissue was fixed in 10% formalin for 48 h and
was embedded in paraffin. Sections (5 µm) were stained with
hematoxylin and eosin (HE), fluorescein isothiocyanate (FITC)-
labeled lectin wheat germ agglutinin (Sigma, St. Louis, MO,
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FIGURE 2 | Expression of transcription factor Foxp3 in neonatal rat ventricular myocytes (NRVM). Hypertrophic response of NRVM was induced by
angiotensin II (Ang II). (A) Expression of Foxp3 (green) was detected using double-label immunofluorescence staining with α-actinin (red). Cells were co-stained with
DAPI to visualize their nuclei (blue). Images from the same field were merged. (bar = 20 µm); (B) Expression intensity level of Foxp3; (C) Ratio of Foxp3 expression in
nucleus to that in cytoplasm. The data are presented as mean ± SEM, ∗∗p < 0.01 compared with the control group;#p < 0.05, ##p < 0.01 compared with the Ang
II-treated group (one-way ANOVA).
USA), as well as Masson’s trichrome (Chen et al., 2011). Cross-
sectional areas (CSA) were measured using the Image Pro Plus 5.1
image analysis program (Media Cybernetics, Silver Spring, MD,
USA). Fibrosis percentage was calculated as the ratio of fibrotic
area to total LV area (Pereira et al., 2014; Matsuo et al., 2015).
Immunohistochemistry
The paraffin sections were manufactured as described previously.
α-MHC, β-MHC and Foxp3 monoclonal antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) were used at a
dilution of 1:200 according to the manufacturer’s instruction.
To visualize this reaction after incubation with a secondary
antibody at room temperature, the slides were incubated with
3,3 N-diaminobenzidine tetrahydrochloride (DAB). The reaction
was stopped by immersing the slides in distilled water, and then
the sections were counterstained with haematoxylin, mounted
and examined. The OD values were calculated by Image Pro-
Plus5.1 (Media Cybernetics, Silver Spring, MD, USA).
Serum Troponin I Assay
The levels of serum troponin I (cTnI) were measured with
the Abbott automatic chemiluminescence immunoassay analyzer
(Architect i2000SR; Abbott Diagnostics, Abbott Park, IL, USA).
The detection routine was referred to FLEX TM technology with
cTnI reagent.
Serum Brain Natriuretic Peptide Assay
The levels of serum brain natriuretic peptide (BNP) were
quantified by enzyme-linked immunosorbent assay (ELISA) kits
and performed according to the manufacturer’s instructions
(R&D systems, Minneapolis, MN, USA) in accordance with the
Double-antibody Sandwich ELISA instructions. The BNP values
were calculated by standard curve method.
Real-Time Reverse Transcription PCR
Total RNA was extracted from NRVM and LV tissue using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Only highly pure RNAs (OD260/
OD280 in the range of 1.80–2.10) were used for downstream
assays. RNA was reverse transcribed with the PrimeScript RT
reagent kit (TaKaRa, Japan). Real-time PCR for α-MHC,
β-MHC and Foxp3 mRNA was performed using the following
primers designed by Premier 5.0 (Premier Biosoft Inter-
national, Palo Alto, CA, USA) for α-MHC (forward: 5′-GCCG
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FIGURE 3 | Triptolide attenuated cardiac hypertrophy in mice. Cardiac hypertrophy was induced by isoproterenol (Iso, 5 mg/kg, s.c., for 14 days) in mice
(n = 8–10 in each group). (A) Body weight; (B) heart weight (HW) index to tibia length (TL); (C) left ventricular weight (LVW) indexes to TL; (D) α-myosin heavy chain
(MHC) mRNA expression level; (E) β-MHC mRNA expression level; (F) atrial natriuretic peptide (ANP) mRNA expression level. These mRNA expression levels were
measured with Real-time PCR method and normalized to β-actin and control group, respectively. The data are presented as mean ± SEM, ∗∗p < 0.01 compared
with the control group; #p < 0.05, ##p < 0.01 compared with the Iso-treated group (one-way ANOVA).
AGTCCCAGGTCAACA-3′, reverse: 5′-TATTGGCCACAGCG
AGGGTCT-3′), β-MHC (forward: 5′-GGCAAGACGGTG AC
TGTGAAGG-3′, reverse: 5′-GGTTGACGGTGACGCAGAAG
AG-3′), ANP (forward: 5′-GAGGAGAAGATGCCGGTAG-3′;
reverse: 5′-CTAGAGAGGGAGCT AAGTG-3′), Foxp3 (forward:
5′-ACTGGGCTTCTGGGTATGTC-3′; reverse: 5′-TAGCTTG
CG GCTCCTAATGC-3′), and β-actin (forward: 5′-GTCCCTC
ACCC TCCCAAAAGC-3′; reverse: 5′-CACAGAAGCAATGC
TGTCACCT-3′). The reaction was performed in a total volume
of 25 µl with QPK-201 SYBR Green PCR Master Mix (Takara,
Shiga, Japan) using the following conditions: after an initial 5 min
at 94◦C, the samples were submitted to 38 cycles comprising 30
s at 94◦C for denaturation, 30 s at 62◦C for annealing, and 45 s
at 72◦C for elongation. Finally, 10 min at 72◦C for ending this
reaction. The Ct (cycle threshold) values were normalized to both
the β-actin expression level and the normal controls, and the
relative quantification was calculated using the 2−11Ct method
(Livak and Schmittgen, 2001; Zwadlo et al., 2015).
Statistical Analysis
The results are expressed as the mean ± standard error of mean
(SEM). The data were analyzed by one-way analysis of variance
(ANOVA) with least significant difference (LSD) post hoc analyses
(SPSS, Chicago, IL, USA) and GraphPad Prism version 5.01
(GraphPad Software, La Jolla, CA, USA). The survival rate was
compared with χ2 test. The value of P less than 0.05 was
considered statistically significant.
RESULTS
Hypertrophic Response of NRVM
After stimulation with AngII for 24 h, the surface area of
primary cardiomyocytes significantly increased by 1.83-folds
compared to the control (AngII vs. control: 3849 ± 81 vs. 1379
± 31 µm2; p < 0.01). The three dose of TP (1, 3 or 10 µg/L)
treatment reduced cardiomyocyte size significantly
(Figures 1A,B). Moreover, the mRNA and protein expression
of β-MHC, which is a marker of cardiac hypertrophy and is
induced by disease-related hypertrophic stimuli in rat ventricular
myocytes, increased dramatically after AngII stimulation
(Figures 1C,D). Simultaneously, TP decreased the expressions
of β-MHC and its mRNA significantly by comparison to those in
AngII group, respectively.
Expression of Foxp3 in NRVM
Double-immunofluorescence staining was used to colocalize
Foxp3 (green) with cardiomyocytes (anti-α-actinin, red). Foxp3
was expressed in both the cytoplasm and nuclei (Figure 2A),
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FIGURE 4 | Myocardial histological changes after triptolide treatment. Cardiac hypertrophy was induced by isoproterenol (Iso, 5 mg/kg, s.c., for 14 days) in
mice (n = 8–10 in each group). The mice were treated with normal saline, Iso, and triptolide (10, 30, 90 µg/kg), respectively, for 14 days. (A) hematoxylin and eosin
(HE) staining (bar = 50 µm), Wheat germ agglutinin lectin staining (bar = 50 µm) and Masson’s trichome staining (bar = 50 µm); (B) Cross-sectional area;
(C) Fibrosis score. The data are presented as mean ± SEM, ∗∗p < 0.01 compared with the control group; ##p < 0.01 compared with the Iso-treated group
(one-way ANOVA).
and the expression intensity in the nuclei was significantly higher
than that in the cytoplasm in all groups (p < 0.01). Compared
with the control group, the expression level of Foxp3 in myocytes
treated with AngII decreased markedly. TP (3 and 10µg/L) could
significantly elevate Foxp3 expression by comparison to that in
the AngII-treated group (Figure 2B). Furthermore, the ratio of
nuclear to cytoplasmic expression of Foxp3 decreased after AngII
treatment (p< 0.01) and increased in TP treated groups (p< 0.05
or 0.01) (Figure 2C).
Survival of Mice
During the whole experimental period, one mouse in the control
group, two mice in the Iso group and one in the 10 µg/kg TP
group were sacrificed before the humane endpoints. There were
no significant differences in mortality between all the groups.
Myocardial Hypertrophy
The heart and LV weight indexes were measured to evaluate
the cardiac hypertrophic response. The weight of the heart and
LV in the Iso group were increased 15.6% (p < 0.05) and
19.6% (p < 0.05) respectively compared to those in the control
group. After treatment with TP 30 and 90 µg/kg, all the heart
indexes, including HW/BW, LVW/BW, HW/TL, and LVW/TL,
were decreased markedly compared with those in the Iso group
(p< 0.05 or 0.01). In the 30 and 90 µg/kg group, TP reduced the
ratio of LV to TL by 13.4 and 15.6%, respectively (Figures 3A–C).
β-MHC, ANP and the ratio of β-MHC to α-MHC are
considered as the molecular markers of myocardial hypertrophy
(Wang et al., 2002, 2005). mRNA expression level of these
three genes were determined using real-time PCR. Iso treatment
markedly decreased α-MHC mRNA expression level, and
elevated mRNA expression level of β-MHC and ANP, as well
as the ratio of β-MHC to α-MHC mRNA. TP significantly
downregulated the expression of β-MHC and ANP mRNA
compared with those in Iso group (Figures 3D–F).
Histological Findings
Under a light microscope, we found hypertrophic cardio-
myocytes, myocardial fiber disruption, focal necrosis and
inflammatory cell infiltration in the Iso group (Figure 4A,
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FIGURE 5 | The effects of triptolide on the myocardial expression of myosin heavy chains (MHC). Cardiac hypertrophy was induced by isoproterenol (Iso,
5 mg/kg, s.c., for 14 days) in mice (n = 8–10 in each group). The mice were treated with normal saline, Iso, and triptolide (10, 30, 90 µg/kg), respectively, for
14 days. (A) The expression of α- and β-MHC were determined with immunohistochemistry (bar = 10 µm); (B) Expression of α-MHC; (C) Expression of β-MHC. The
data are presented as mean ± SEM, ∗∗p < 0.01 compared with the control group; ##p < 0.01 compared with the Iso-treated group (one-way ANOVA).
HE staining). Iso treatment resulted in a significant increase
in the cross-sectional area (CSA) of cardiomyocytes and LV
interstitial fibrosis compared with the control group. TP (10, 30,
or 90 µg/kg) treatment significantly decreased myocardial tissue
damage and decreased CSA and fibrosis score compared with Iso
group (Figures 4A–C).
Myocardial Expression of α-MHC and
β-MHC
The protein expressions of α-MHC and β-MHC were deter-
mined using immunohistochemistry technique. The result
demonstrated that in the control group α-MHC was expressed
at a high level, but β-MHC was expressed at a hardly detectable
level. Compared with control, the expression of α-MHC was
down-regulated and β-MHC was increased in the Iso group
significantly (p < 0.01). TP treatment could elevate α-MHC
expression but decrease β-MHC substantially. The ratio of
α-MHC to β-MHC, an important index which contributes to
contractile function, decreased in the Iso group and could be
augmented by TP treatment strikingly (Figures 5A–C).
Serum Concentration of cTnI and BNP
To evaluate myocardial injury, the serum concentrations of
cTnI and BNP were determined with chemiluminescence
immunoassay and ELISA, and they increased by 5.78-fold
and 11.87-fold, respectively, compared to the control group
(Figure 6). TP decreased the concentrations of cTnI and BNP
markedly in a dose-dependent manner. cTnI in the TP (10, 30,
90 µg/kg) groups decreased 26.4, 73.6, and 86.5%, and BNP
decreased 31.9, 62.3, and 80.8%, respectively, compared with the
Iso groups.
Myocardial Expression of Foxp3
As shown in Figure 7, myocardial expression of transcription
factor Foxp3 decreased markedly in isoproterenol-induced
cardiac hypertrophy mice compared to those in the control group
(p< 0.01). TP treatment significantly elevated protein expression
of Foxp3. The elevations were correlated significantly with TP
dosage (r = 0.861, p< 0.01).
DISCUSSION
TP is a major active component of Tripterygium wilfordii Hook
F, which has been used for the treatment of autoimmune
diseases for 1000s of years due to its anti-inflammatory
and immunosuppressive effects (Liu, 2011). In recent years,
studies have suggested that TP could cause a decrease in
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FIGURE 6 | The effects of triptolide on serum cardiac troponin-I (cTnI) (A) and brain natriuretic peptide (BNP) (B) in mice. Cardiac hypertrophy was induced
by isoproterenol (Iso, 5 mg/kg, s.c., for 14 days) in mice (n = 8–10 in each group). The mice were treated with normal saline, Iso, and triptolide (10, 30, 90 µg/kg),
respectively, for 14 days. The data are presented as mean ± SEM, ∗∗p < 0.01 compared with the control group; ##p < 0.01 compared with the Iso-treated group
(one-way ANOVA).
FIGURE 7 | Myocardial expression of transcription factor Foxp3. Cardiac hypertrophy was induced by isoproterenol (5 mg/kg, s.c., for 14 days) in mice
(n = 8–10 in each group). The mice were treated with normal saline, Iso, and triptolide (TP, 10, 30, 90 µg/kg), respectively, for 14 days. (A) Expression of Foxp3 was
determined using immunohistochemistry (bar = 20 µm); (B) histogram represented the expression level of Foxp3 (relative integral optical density, OD); (C) Foxp3
mRNA expression level, determined with Real-time PCR. The data are presented as mean ± SEM, ∗∗p < 0.01 compared with the control group;#p < 0.05,
##p < 0.01 compared with the Iso-treated group (one-way ANOVA).
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the GATA-4 DNA binding activity of nuclear factor of
activated T cells (NFAT) and may effectively downregulate
the activity of nuclear factor (NF)-κB (Qiu and Kao, 2003;
Liu et al., 2014). NFAT and NF-κB are involved not only
in regulating cardiac hypertrophy and ventricular remodeling
independently, but also in promoting them synergistically
through a direct interaction that integrates signal pathways
leading to cardiac hypertrophy (Liu et al., 2012, 2014). In
the present study, we found that TP could effectively alleviate
myocardial damage, reduce the left ventricle index and inhibit
the occurrence of myocardial hypertrophy in a dose-dependent
manner.
Inflammation and immunity play an important role in
the development of cardiac hypertrophy. It has become
clear recently that immune imbalance including a decline in
immune cells and factors, along with an obvious increase
in immune cytokines, participates in the development of
cardiac hypertrophy (Barhoumi et al., 2011). Many studies
have demonstrated that immunoregulation and inflammation
control could improve patients’ myocardial contractility, cardiac
function and quality of life through correcting the imbalance of
the lymphocyte subpopulation and inhibiting the myocardium
damage induced by pro-inflammatory factors (Wallace et al.,
2005; Rassi et al., 2009; Straburzyn´ska-Migaj, 2009; Wei,
2011). With the excellent effects of anti-inflammation and
immunosuppression, TP can improve ventricular function
significantly by downregulating NF-κB signaling (Wen et al.,
2013).
The Fox transcription factor family is characterized by
forkhead helix domain, which have various members that
perform different functions. As a main member of this family,
Foxp3 has been shown to execute function in regulating the
inhibition of Treg cells and reducing the immune response
(Stoop et al., 2007). Moreover, in addition to Treg cells,
Foxp3 is found to be expressed in various other cells, such
as many different types of cancer cells (Karanikas et al.,
2008; Ladoire et al., 2011) and epithelial cells from mammary
glands, lung bronchia and prostate glands (Chen et al.,
2008). Foxp3 can associate physically with Rel transcription
factors, such as NFAT and NF-κB, and block the endogenous
expression of their target genes (Bettelli et al., 2005). However,
heretofore, it was unclear whether Foxp3 was expressed in
cardiomyocytes and whether Foxp3 was able to suppress the
development of cardiac hypertrophy. In the present research,
using colocalized immunofluorescence, we found that Foxp3
was expressed in cardiomyocytes, and its expression was
downregulated by AngII stimulation. TP treatment elevated
Foxp3 expression and its translocation from cytoplasm to nuclei.
Immunohistochemistry and quantitative PCR showed that Foxp3
and its mRNA were expressed in normal myocardium, and
myocardial expression of them was decreased markedly in
cardiac hypertrophy mice. TP treatment significantly elevated
mRNA and protein expression of Foxp3. By this mean,
up-regulation of Foxp3 could directly inhibit NFAT activity
in myocardial cells, which may attenuate the development
of myocardial hypertrophy (Liu et al., 2012). Additionally,
the anti-inflammatory and immunosuppressive effects of TP
could also be involved in inhibiting the process of cardiac
hypertrophy.
Our study still has certain limitations. Although the expres-
sion of Foxp3 were determined with colocalization immuno-
fluorescence in cardiomyocytes and immunohistochemistry in
myocardial tissue, more researches need to be performed to
confirm the role and molecular mechanism of myocardial
Foxp3 in the development of cardiac hypertrophy using the
knockout animals and genetic inhibition technique. In addition,
we observed the cross-sectional area of cardiomyocytes from
histological sections by using FITC-labeled lectin staining.
Lectin is a type of carbohydrate-binding protein, which
may bind not only soluble extracellular and intercellular
glycoprotein, but also the carbohydrate moity of glycolipid.
This staining method is not as sensitive and accurate as
vinculin immuohistochemistry for the measurement of cell
area (Santos-Gallego et al., 2016). Vinculin is a membrane-
cytoskeletal protein in focal adhesion plaques, which is more
speciafically localized to the ends of actin filaments (Hirsch et al.,
1996).
CONCLUSION
Triptolide can effectively alleviate myocardial hypertrophy by
inhibiting left ventricular remodeling, elevating the myocardial
expression of Foxp3, and correcting the imbalance of expression
of α-MHC and β-MHC. Transcription factor Foxp3 and
inflammatory factors are involved in the process of cardiac
hypertrophy and pathological remodeling, which provide a
new approach for the prevention and treatment of cardiac
hypertrophy.
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